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Abstract: Parkinson’s disease (PD) is a common neurodegenerative disorder that primarily afflicts
the elderly. It is characterized by motor dysfunction due to extensive neuron loss in the substantia
nigra pars compacta. There are multiple biological processes that are negatively impacted during the
pathogenesis of PD, and are implicated in the cell death in this region. Neuroinflammation is evidently
involved in PD pathology and mitigating the inflammatory cascade has been a therapeutic strategy.
Age is the number one risk factor for PD and thus needs to be considered in the context of disease
pathology. Here, we discuss the role of neuroinflammation within the context of aging as it applies
to the development of PD, and the potential for two representative compounds, fractalkine and
astaxanthin, to attenuate the pathophysiology that modulates neurodegeneration that occurs in
Parkinson’s disease.
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1. Parkinson’s Disease
Parkinson’s disease (PD) is a debilitating condition that affects millions of people worldwide.
With the development of drugs to treat complications associated with significant morbidity and
mortality, patients are living up to 20 years after the diagnosis of PD. Although the use of medications
has led to a relative improvement in quality of life, these patients are often substantially disabled,
requiring significant health care and compensation for loss of wages. It has been projected that
the prevalence of PD will double by 2040, indicating severe economic consequences to come as
the incidence increases. There are currently no available medications that prevent or reverse the
neurodegeneration that causes these disabilities [1].
Parkinson’s disease is primarily characterized neuroanatomically by the degeneration of the
neurons in the substantia nigra pars compacta (SN), resulting in a substantial loss of dopamine
(DA) afferents to the striatum and subsequent motor impairment. It is estimated that nearly 50% of
dopaminergic cells in the SN have been lost prior to clinical presentation of motor dysfunction.
It is now understood that PD pathology extends to extra nigral regions including the locus
coeruleus, nucleus basalis of Meynert, peduculopontine nucleus, intralaminar thalamus, and lateral
hypothalamus suggesting dysfunction and neurodegeneration in many areas of the brain [2]. It is
histopathologically characterized by the formation of Lewy bodies, intraneuronal protein inclusions
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comprised predominantly of α-synuclein (α-syn). These protein aggregates have been observed
throughout the brain, and pathological α-syn deposition is thought to begin in the medulla and spread
throughout the midbrain to cortical regions in a manner that corresponds to the onset of clinical
symptoms [2]. These protein aggregates are associated with microgliosis [3], and impaired cellular
physiology, although the precise mechanisms leading to cytotoxicity are currently unknown.
The vast majority of Parkinson’s disease cases are classified as idiopathic, but approximately 5%
of PD cases are genetically linked. There are several gene mutations that confer susceptibility or are
associated with the development of PD, including mutations in leucine-rich repeat kinase 2 (LRRK),
PTEN Induced putative kinase 1 (PINK1), and the protein deglycase (DJ1). However, α-syn has proven
to have a very strong association and relevance to PD and similar disorders collectively known as
synucleinopathies. Abnormalities in the SNCA gene that encodes the α-syn protein are strongly
correlated with the development of an autosomal dominant familial form of PD [4]. Multiplications of
the SNCA gene are known to increase the expression of the α-syn protein, whereas certain missense
mutations of the gene (A53T, A30P, E46K) produce variants of α-syn, both of which have known
pathological attributes related to the increased propensity to aggregate.
The physiological role of α-syn, along with the isoforms β- and γ-synuclein, is related to
neurotransmission, and they are primarily located in the synapse. Increased concentrations of α-syn
protein or mutated forms of α-syn make the protein susceptible to misfolding and polymerization
by self-assembly. These misfolded aggregates have heterogeneous conformations that have not been
clearly elucidated. These aggregates are associated with various deleterious biological activities
including (1) the permeabilization of the cellular membranes [5], associated with an alteration of
intracellular ion concentrations [6]; (2) disruption of energy production through interactions with the
mitochondria [7]; and (3) interruption of intracellular transport via physical interference of motor
proteins, or direct interaction with organelles and vesicles [8]. The formation of soluble oligomeric
species is presumed to be relatively more toxic than fibrils, through the energetically favorable
association within the phospholipids that forms pores in the cellular membrane [9]. The amount
of LB formations throughout the brain reflects the severity of impairment [10]. However, it has been
postulated that the organizing of fibrils into Lewy Bodies may serve as a protective mechanism to
divert toxic aggregate species into less harmful formations to preserve normal cellular physiology [11].
2. The Interaction with Aging
Aging is a major risk factor for the development of PD [12], evidenced by the fact that the
incidence increases for every decade over 50 years of age. While aging contributes to PD, it is also
underrepresented in PD research, as it is common for the experimental models to be carried out using
young animals. However, the impact of aging is essential to consider in terms of the disease process
because many of the physiological changes that occur in aged animals can drive or exacerbate the
pathological mechanisms that lead to PD and alter both the course and tempo of the disease.
The impact of aging on the incidence of PD is compounded by the fact that the dopaminergic
neurons of the SN seem to have a unique vulnerability to cellular stressors in the microenvironment [12].
Although it is not completely understood what sets these cells apart from those of other DA pathways,
the neurons of this nucleus are more susceptible to the homeostatic disturbances and degenerate
significantly more compared to similar or adjacent regions [13]. This can be grossly attributed to high
oxidative stress and inflammation. It is known that the SN is exposed to higher levels of oxidation
compared to other dopaminergic centers [11]. This is partly due to an unusually high concentration of
iron, which through the Fenton reaction, can generate free radicals, as well as nitric oxide released
by microglia that densely populate this region [14,15]. In addition to the accumulation of reactive
oxygen and nitrogen species, the SN is also ill-equipped to neutralize them, due to a low expression
of glutathione, an important endogenous antioxidant molecule, leading to an inevitable increase in
oxidative stress [16]. Aging is also associated with increased levels of oxidative stress and altered
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microglial function and this combined with the SN’s reduced resilience to reactive oxygen species
(ROS) could promote neurodegeneration.
The role of neuroinflammation in PD is also particularly important in the context of aging.
Inflammation is known to increase with age. This is largely attributed to the age related changes in
microglial physiology. Microglia, myeloid derived macrophages, are the resident immune cell of the
CNS and constitute 10% of the cell population. Their highly ramified processes are highly motile
and constantly survey parenchyma, facilitating the detection and the cellular response to infection
and injury. However, microglia are also involved in many homeostatic functions and are now known
to be highly active during post-natal synaptic pruning and synaptic plasticity [17,18]. Microglia are
known to undergo a phenomenon known as priming with age. This describes a propensity for
microglia to attain a pro-inflammatory state and is characterized by 4 principal features: (1) primed
microglia will exhibit higher levels of inflammatory mediators and surface makers even in the absence
of immune stimulation; (2) microglia also demonstrate hyperactivity upon subsequent activation
where they release exaggerated amounts of cytokines and reactive oxygen/nitrogen species; (3) they
are also resistant to regulatory mechanisms that typically restore microglia back to their inactivated
state, causing them to remain in an aggravated state for a longer period of time [19]; and (4) they
do not respond to stimuli, such as IL4, that promote anti-inflammatory factors, angiogenesis, and
neurotrophic factor secretion [19,20]. For example, Lee, Ruiz et al. (2013) induced microglial activation
in the brains of young and old mice with the application of a cytokine cocktail designed to elicit an M1,
pro-inflammatory phenotype (IL1β + IL12) or an anti-inflammatory, M2 phenotype (IL-4 + IL-13).
These authors demonstrated that M1 cocktail elicits an increased response microglia from the aged
brain, while the same aged cells were less responsive to the M2 cocktail. This phenomenon has been
reproduced with isolated microglia and has been termed priming [21].
In order to elucidate the molecular underpinnings of the age-related alterations in microglial
function, numerous researchers have begun to assess the differential expression of genes and protein
in primary microglia. A recent study using RNAseq comparing the transcriptional profiles of isolated
microglia to whole brain has identified the microglial sensome [22]. These authors further assessed
the sensome in microglia isolated from aged animals and demonstrated that many of the genes
related to sensing endogenous ligands were down regulated, whereas genes pertaining to host defense
were up-regulated. Furthermore, another recent study using gene microarrays of isolated microglia
identified an up-regulation of NFκB related genes in these aged cells [23]. Sustained microglial
activation and microglial priming can perpetuate neurodegeneration by increasing cellular stress both
from enhanced release of cytotoxic substances, but also from the loss of trophic support as a result of
impaired microglial homeostatic function.
3. Role of Neuroinflammation
The precise pathophysiology that precipitates the development of PD is unknown,
although it is understood that a few key biological processes are often impacted in patients,
including mitochondrial function, proteostaisis, immune function leading to oxidative stress and
inflammation. Neuroinflammation is critical factor in the disease process that clearly contributes
significantly to the neurodegeneration seen in PD. However, it is difficult to ascertain if inflammation
initiates pathological features of PD, or is triggered by the widespread protein aggregation and neuronal
death that occurs during disease progression. McGeer et al. (1988) described the presence of increased
reactive gliosis and infiltrating T-cells around the SN in post mortem analysis of PD brains [24].
Their observations provided some of the first indications that increased neuroinflammation is
associated with DA cell death. Many other studies have reported features of inflammation in
post-mortem samples, such as increased levels of inflammatory mediators like iNos and Cox-2 [25],
supporting the contribution of increased neuroinflammation during advanced stages of the disease.
Similar patterns of activated microglia have been detected in the brain areas associated with clinical
symptoms of the disease [26]. Interestingly, this distribution of gliosis was evident in both newly
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diagnosed patients and those with advanced pathology. Elevated levels of pro-inflammatory cytokines
have also been detected in the cerebrospinal fluid and plasma of PD patients at early stages of the
disease. These findings suggest that microglial activation may be initiated in early stages and remain
an ongoing process throughout the disease. Furthermore, inflammatory insults and injuries are known
to increase the risk of developing PD. Traumatic brain injuries (TBI) have been linked to an increased
risk of developing the disease in a frequency and severity dependent manner; multiple injuries or
injuries requiring hospitalization were more strongly correlated with PD onset [27]. This occurrence is
largely attributed to the neuroinflammatory cascade that follows trauma. Certain infections causing
neuroinflammation have been known to lead to a post-encephalitic Parkinsonism. This may be
because the SN is densely populated by microglia [28], rendering it is especially susceptible to
inflammatory stimuli. For example, intracranial injections of lipopolysaccharide (LPS), a bacterial
antigen, dramatically activate microglia and leads to nigrostriatal degeneration and motor symptoms of
PD [29]. Parkinsonism is a separate condition distinct from PD, but these observations of inflammatory
insults leading to cell death may have important implications for PD itself. Taken together, these data
suggest a potential role of neuroinflammation in ongoing cell death that occurs in PD.
Furthermore, pathological forms of α-syn are associated with microglial activation in the brains of
PD patients and this is consistently recapitulated in animal models. The presence of α-syn aggregates
modulates glial activity, often eliciting the release of inflammatory mediators. Codolo et al. (2013)
treated monocytes with various species of α-syn to demonstrate that the aggregated and pathogenic
forms of the protein can facilitate the secretion of IL-1β though stimulation of the inflammasome [30].
The nitration of α-syn is a common modification associated with pathology thought to be promoted in
an oxidative environment. Stimulation of microglial cells with nitrated and aggregated α-syn alters
the cellular morphology and transcriptional profile to a pro-inflammatory phenotype, with increased
transcription of IL-1β, TNF-α, and IFN-γ as well as induction of NF-Kβ signaling [31]. Additionally,
this α-syn activation of microglia seems to be related to phagocytic capacity, as inflammatory cascades
and activation of NADPH oxidase are initiated after the glial cells take up the aggregates [3,32,33].
Zhang et al. (2005) demonstrated that impeding phagocytosis of primary microglia attenuates the
release of superoxide from these cells when exposed to α-syn in vitro. This detection and engulfment
of α-syn seems to be dependent on the FCγ receptor, as FCγ deficient mice are protected the
resultant neurodegeneration from AAV driven over expression of α-syn [32,33]. It is thought that this
inflammatory response to abnormal α-syn will perpetuate neural dysfunction through the release of
cytotoxic compounds that leads to cell death. Many of these studies were done using either glial cell
lines or in young animals, neglecting the impact of the pro-inflammatory actions of α-syn within the
primed glial environment of an aging brain, thus causing even more damage. In fact, when α-syn is
introduced into an aged animal it is more cytotoxic compared to the young controls [34].
4. Fractalkine as an Anti-Inflammatory Treatment
There is promising pre-clinical experimental evidence to support that reducing inflammation,
specifically by suppressing microglial activity, can modify the progression of the loss of DA
neurons [35–38]. Non-steroidal anti-inflammatory drugs have been suggested to reduce the risk
of PD onset [39]. Also, the use of minocycline, a tetracycline with pharmaceutical actions that extend
beyond the classical antimicrobial activity, has been shown to reduce cell death in a neurotoxic
model of PD using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These researchers attributed
the neuroprotective effect to the down-regulation of iNOS expression and glial activation [40].
Minocycline was also shown to inhibit apoptosis through a reduction of related inflammatory
mediators [41]. Because glial activation is associated with the release of pro-inflammatory factors
capable of damaging neurons, this data suggests that mediating the excessive inflammation in
PD is a viable therapeutic strategy. There are several signals produced by neurons that have
an anti-inflammatory action on microglia, including CD200, CD22, CD47 and fractalkine (FKN, CX3CL1),
which could be potential therapeutic targets.
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Fractalkine is a protein expressed constitutively by neurons in a membrane bound form that
can be cleaved by disintegrin and metalloproteinase (ADAM) 10 and 17. This proteolysis releases
a soluble form of the protein, but both isoforms are thought to ligate the cognate receptor, CX3CR1,
located on the surface of microglia in the CNS [42]. This neuron-glia interaction serves as an important
endogenous mechanism to suppress microglial activation and regulate the output of inflammatory
mediators and other damaging molecules [42]. It has been shown that increasing fractalkine levels
using an AAV9 gene therapy approach can be neuroprotective [35,36], while the absence of this
FKN-CX3CR1 signaling cascade confers susceptibility to neurodegeneration in rodent models of PD.
Cardona et al. (2006) demonstrated that CX3CR1 deficiency lead to increase neurotoxicity to both
peripheral LPS and MPTP injections. In these experiments, both heterozygous and homozygous
mice exhibited increased neurodegeneration and IL-1β expression compared to the intact wild-type
controls [43]. There is evidence indicating that fractalkine can regulate microglial function and
subsequently reduce inflammation in the CNS. Multiple in vitro studies have established that
enhancing fractalkine signaling through application of the ligand or stimulation of the receptor
can protect against cell death in culture; FKN-ligand decreases microglial apoptosis and protects
against neurotoxicity by both LPS and TNF-α. It has been demonstrated that maintaining or
enhancing communication of FKN/CX3CR1 is neuroprotective in multiple rodent models of PD.
Pabon et al. (2011) [37] attenuated the neurotoxicity of 6 hydroxydopamine (6OHDA) by delivering
a chronic intrastriatal infusion of recombinant fractalkine ligand. This preservation of dopaminergic
terminals in the striatum was also associated with decreased microglial activation around the lesion
site, indicated by a reduced expression of the MHCII surface marker. To further examine the action
of fractalkine in a model of PD where synuclein is introduced in the SN via AAV, Nash et al. (2015)
corroborated the neuroprotective effects of FKN by using a viral vector to over express the different
isoforms of FKN; membrane-bound (mFKN) or the soluble portion (sFKN). In this study, sFKN reduced
DA cell death in young rats with overexpression α-syn in the SN via AAV9. These findings may
be due to altered FKN-CX3CR1 signaling [44] and a reduction in pro-inflammatory cytokines and
modulation of microglial function into a more protective role (Figure 1). These results suggest that
supraphysiological levels of the fractalkine are protective against the neurodegeneration occurring in
two separate experimental models of PD. Morganti et al. (2012) [36] also illustrated the importance
of neuron-glial communication by administering MPTP to animals deficient in the fractalkine ligand.
These FKN knockouts were extremely susceptible to MPTP toxicity, and display both a dramatic loss
of TH in the SN and the robust gliosis associated with the lesion site. Not only does this work indicate
that FKN-CX3CR1 communication is necessary for moderating cell death and subsequent detrimental
inflammatory events, but it also suggests that further enhancing or supplementing this signaling
pathway above baseline activity is sufficient to achieve neuroprotection against these potent toxins
(Figure 1). However, the action of fractalkine is quite complex; CX3CR1 knockout mice have been
shown to increase phagocytosis of amyloid, but decrease phagocytosis of synuclein [44]. It is unclear if
this action is mediated by membrane bound fractalkine or the cleaved, soluble form. Several studies
have tried to clarify the roles of the differential processing of fractalkine and there does not appear to
be a clear conclusion at this point. When an obligate soluble version of fractalkine is used, as described
here with a gene therapy approach, it has been shown to be beneficial in models of PD and AD tau
pathology [35,36,45]. However, in other models where an obligate soluble fractalkine mouse is used,
opposite results have been observed, and this paper concludes that the membrane anchored fractalkine
is associated with phagocytosis of Aβ [46].
Much of the current data regarding the therapeutic potential of FKN in the treatment of
inflammatory and neurodegenerative conditions stems from studies involving young animals.
However, it is essential to note that aged microglia have been shown to be resistant to their regulatory
signals [20,47]. Furthermore, communication via the FKN/CX3CR1 axis becomes dysregulated
with age and can also contribute to microglial priming and dysfunction. There are age associated
changes affecting both the ligand and receptor. It has been has shown that FKN is reduced by
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in the aged hippocampus [48], although the extent of FKN downregulation in the SN has not yet
been fully characterized. Additionally, immune challenges in the aged CNS lead to a prolonged
down regulation of the fractalkine receptor that is associated with a sustained inflammatory response,
further compromising this protective neuron glia interaction [49]. Therefore, it is imperative to investigate
the therapeutic potential of FKN in the treatment of PD in aged animal models; future studies are needed
to examine the efficacy of FKN on aged or primed microglia.Brain Sci. 2016, 6, 41  6 of 12 
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There is substantial evidence indicating that treatment with astaxanthin causes a reduction in 
the markers of cellular stress due to excess ROS production, such as 8-isoprostane, protein carbonyl 
moieties and 8OHdG [56]. Additionally, astaxanthin has been shown to increase the efficacy of 
endogenous antioxidant mechanisms in vivo including increasing the expression or activity of 
glutathione, catalase, thioredoxin reductase and superoxide dismutase (SOD) [57,58]. It has also been 
shown to upregulate heme-oxygenease 1 (HO-1) through increase in NRF [59,60]. These findings 
suggest that astaxanthin treatment may help alleviate some of the ongoing oxidative stress that occurs 
during the progression of PD as it contributes to cellular dysfunction.  
However, in addition to oxidative damage, there are a number of physiological changes that 
occur with age that exacerbate the cellular stress in the SN. Mitochondrial dynamics, proteosomal 
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There is substantial evidence indicating that treatment with astaxanthin causes a reduction in
the markers of cellular stress due to excess ROS production, such as 8-isoprostane, protein carbonyl
moieties and 8OHdG [56]. Additionally, astaxanthin has been shown to increase the efficacy of
endogenous antioxidant mechanisms in vivo including increasing the expression or activity of
glutathione, catalase, thioredoxin reductase and superoxide dismutase (SOD) [57,58]. It has also
been shown to upregulate heme-oxygenease 1 (HO-1) through increase in NRF [59,60]. These findings
suggest that astaxanthin treatment may help alleviate some of the ongoing oxidative stress that occurs
during the progression of PD as it contributes to cellular dysfunction.
However, in addition to oxidative damage, there are a number of physiological changes that
occur with age that exacerbate the cellular stress in the SN. Mitochondrial dynamics, proteosomal
efficiency [61] and levels of synuclein [62] are all altered with age, likely rendering the DA cells
more vulnerable to neurodegeneration. Aging also leads to microglial priming and may facilitate
PD disease progression. Chronic microglial activation results in prolonged exposure to cytotoxic,
pro-inflammatory cytokines, increasing cellular stress and ultimately leading to neurodegeneration [33].
Age_induced primed microglia are hyperactive upon subsequent stimulation and release exaggerated
amounts of cytokines. They are resistant to reversion back to a state of tissue repair and maintenance
of homeostasis, as they are less responsive to regulatory mechanisms [20,63,64]. As stated above,
synuclein aggregation may also directly facilitate the release of these inflammatory mediators. It is
thought that this inflammatory response to abnormal α-syn will perpetuate neural dysfunction through
the release of cytotoxic compounds that overwhelm the DA cells, inevitably leading to cell death.
Given the range of pathological mechanisms involved in neurodegeneration seen in PD,
astaxanthin seems to have a unique potential for the treatment of this disorder. Many diverse biological
activities have been described in the literature that are particular relevant to that pathophysiology of PD,
as well as normal aging. Based on this knowledge, the interaction of aging and parkinsonian symptoms
should be responsive to treatment with astaxanthin. For example, astaxanthin has also been implicated
in modulating microglial activity. Experiments using astaxanthin to treat a transformed microglial
cell line can reduce the expression of IL-6 and iNOS/NO in vitro when exposed to an immune
stimulus such as LPS [65]. These results were corroborated by other studies using aged animals where
astaxanthin reduced the release of nitric oxide [56]. These molecules are released in high amounts by
activated microglia and are associated with neuronal damage; attenuating the output of inflammatory
mediators with astaxanthin may offer some neuroprotection from the inflammatory cascades occurring
in the SN.
Some authors have reported alterations in mitochondrial function after astaxanthin treatment.
Although most of these studies were conducted in vitro, this is of great interest to the treatment of
PD. Mitochondrial dysfunction has been implicated in the etiology of the disorder evidenced by the
common toxins that induce Parkinsonism. Both MPTP and rotenone are used to produce Parkinson’s
models by selectively targeting mitochondria leading to the death of SN neurons. Multiple genetic
mutations of proteins involved in mitochondrial dynamics have been clearly linked to the development
of familial Parkinson’s. Furthermore, some of these mitochondrial proteins are associated with a loss
of function with age, and may contribute to the increased incidence of diagnosis over the lifespan.
Furthermore, it has been demonstrated recently that mitochondria are a significant source of
oxidative stress not only in these DA neurons, but also in additional nuclei known to degenerate in
PD. For example, both the locus coeruleus and SN express L-type calcium channels that allow for
an extraneous calcium influx that taxes the mitochondria [66,67]. The presence of these channels
and their associated calcium burden has been proposed to be a common physiological feature
that contributes to the cellular vulnerability for the brain regions affected in PD. Attenuating this
mitochondrial derived oxidative stress that results from calcium overload has led to the use of calcium
channel antagonists for the treatment of PD [68]. These dihydropyrdines, specifically israpidine,
have been shown to be tolerable and safe among PD patients are now in Phase III clinical trial [69].
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The success of these drugs lends support for the therapeutic use of AXT as well. There is
substantial evidence to suggest that astaxanthin works at the level of the mitochondria. According to
HPLC analysis of cellular fractions, astaxanthin will accumulate in mitochondria, and has the capacity
to increase mitochondrial activity as indicated by increased respiration and mitochondrial membrane
potential (MMP) [70]. Mitochondrial dysfunction is a common pathophysiological observation
in PD, and is recapitulated in the α-synuclein model. It has been shown that treating isolated
mitochondria with α-synuclein oligomers induced mitochondrial dysfunction by inhibiting complex 1
and associated with reduced calcium retention time, release of ROS and induced mitochondrial
swelling [7]. In specific studies related to PD, astaxanthin has been shown to protect SH-SY5Y cells
from 6-OHDA [53]. In a similar experiment, astaxanthin treatment mitigated cytotoxicity in PC12 cells
from MPP+ induced cytotoxicity. MPP+ is a toxic metabolite of the dopaminergic neurotoxin MPTP
used in experimental animal models of PD [71]. These cell culture results were corroborated by an
in vivo study using astaxanthin to prevent the neurodegeneration in the SN in response to dose of
MPTP (1 i.p. dose 30 mg/kg daily for 28 days) [54]. This treatment regimen effectively protected
against the loss of tyrosine hydroxylase in the SN and striatum after chronic exposure to the neurotoxin.
However, it is important to understand that many drugs that have been successful in some pre-clinical
models of PD have failed to translate to patients with PD. Developing and testing pre-clinical models
involving disease relevant proteins such as α-synuclein and the impact of aging must be considered
for future studies.
6. Conclusions
Parkinson’s disease is primarily characterized by degeneration of the dopaminergic neurons of
the substantia nigra. The pathophysiology underlying this cell death is not yet clearly understood,
although it is evident that many biological processes are impaired in this vulnerable brain region,
explaining the rapid deterioration of the SN with age. Neuroinflammation is an integral factor
perpetuating cellular damage during progression of the disease, and efforts to mitigate the
inflammatory cascade have been successful in experimental settings, suggesting that anti-inflammatory
treatments are a viable therapeutic strategy to employ in managing Parkinson’s disease. Fractalkine
signaling has proven to be a critical pathway in inflammation-mediated cell death that occurs in animal
models of PD. Astaxanthin has diverse biological activities that have been reported in the literature,
many of which seem to directly oppose the pathological mechanisms involved in neurodegeneration
of the SN. Both fractalkine and astaxanthin represent two promising novel therapeutic agents for the
treatment and management of PD.
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